The new drug is the first FDA-approved option for this indication in more than 15 years and contains significantly less sodium than a current standard-of-care option.
The FDA has proposed new draft guidance to improve the accuracy of pulse oximeters across all skin tones, addressing long-standing concerns about potential disparities in performance.
